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Abstract
Ankylosing spondylitis (AS) is a common inflammatory arthritic condition. Overt inflammatory bowel disease (IBD) occurs in
about 10% of AS patients, and in addition 70% of AS cases may have subclinical terminal ileitis. Spondyloarthritis is also
common in IBD patients. We therefore tested Crohn’s disease susceptibility genes for association with AS, aiming to identify
pleiotropic genetic associations with both diseases. Genotyping was carried out using Sequenom and Applied Biosystems
TaqMan and OpenArray technologies on 53 markers selected from 30 Crohn’s disease associated genomic regions. We tested
genotypes in a population of unrelated individual cases (n= 2,773) and controls (n = 2,215) of white European ancestry for
association with AS. Statistical analysis was carried out using a Cochran-Armitage test for trend in PLINK. Strong association
was detected at chr1q32 near KIF21B (rs11584383, P= 1.6610210, odds ratio (OR) = 0.74, 95% CI:0.68–0.82). Association with
disease was also detected for 2 variants within STAT3 (rs6503695, P=4.661024. OR= 0.86 (95% CI:0.79–0.93); rs744166,
P= 2.661025, OR=0.84 (95% CI:0.77–0.91)). Association was confirmed for IL23R (rs11465804, P= 1.261025, OR=0.65 (95%
CI:0.54–0.79)), and further associations were detected for IL12B (rs10045431, P= 5.261025, OR= 0.83 (95% CI:0.76–0.91)),
CDKAL1 (rs6908425, P=1.161024, OR= 0.82 (95% CI:0.74–0.91)), LRRK2/MUC19 (rs11175593, P= 9.961025, OR=1.92 (95% CI:
1.38–2.67)), and chr13q14 (rs3764147, P= 5.961024, OR=1.19 (95% CI: 1.08–1.31)). Excluding cases with clinical IBD did not
significantly affect these findings. This study identifies chr1q32 and STAT3 as ankylosing spondylitis susceptibility loci. It also
further confirms association for IL23R and detects suggestive association with another 4 loci. STAT3 is a key signaling molecule
within the Th17 lymphocyte differentiation pathway and further enhances the case for a major role of this T-lymphocyte
subset in ankylosing spondylitis. Finally these findings suggest common aetiopathogenic pathways for AS and Crohn’s disease
and further highlight the involvement of common risk variants across multiple diseases.
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Introduction
Ankylosing spondylitis (AS) is one of a group of common
inflammatory rheumatic diseases known as spondyloarthritidies in
which involvement of the spine and sacroiliac joints is prominent
[1]. Heritability of the disease assessed by twin studies has been
determined to be .90% [2]. Apart from the well known HLA-B27
association, recent genetic studies have identified ERAP1, IL23R
and 2 intergenic regions at chr2p15 and chr21q22 as genes/loci
associated with AS [3,4]. However, these alleles only explain a
fraction of the overall genetic risk for AS, and other loci are also
expected to contribute to susceptibility.
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There is increasing interest in the genetics community in the
study of genetic findings from related diseases to identify pleiotropic
genes, as an efficient method to identify further disease-associated
variants. Findings from genome-wide association (GWA) studies
have identified susceptibility genes common to different diseases,
particularly in autoimmune conditions [5]. For example, variants in
PTPN22 are associated with rheumatoid arthritis (RA), type-1-
diabetes (T1D) and Crohn’s disease (CD). Thus far, only the gene
IL23R (associated with AS) has also been found to be associated with
inflammatory bowel disease (IBD) and psoriasis, although the three
conditions commonly occur in the same patients, and are co-
familial. About 10% of AS patients have overt IBD, and in addition
about 70% of AS cases have subclinical terminal ileitis [6]. Gut
inflammation is frequent in patients with spondylarthritis, and one-
quarter of patients who have chronic spondyloarthritis have some
features of CD [7]. Spondyloarthritis is also common in IBD
patients. Axial and peripheral arthritis can occur in up to 30% of
patients with IBD [8]. The prevalence of axial involvement in IBD is
10–20% for sacroiliitis and 3–12% for spondylitis [9], while
radiographic evidence of sacroiliitis is reported in 10–51% of
patients with IBD [10]. A study of families of AS probands (n= 205)
and of healthy controls (n= 1,352) in the Icelandic population
demonstrated evidence to support a common genetic component
for AS and IBD [11]. In addition to confirming the known
familiality of both conditions, the study demonstrated a risk ratio of
3.0 and 2.1 in 1st and 2nd-degree relatives respectively, for the
occurrence of AS in families of probands with IBD, and with the
occurrence of IBD in families of patients with AS. It therefore seems
likely that common pathogenic pathways may act in the
development of both diseases and may be major players in chronic
inflammatory disorders. We therefore sought to investigate CD risk
variants for association with AS in order to explain the co-
occurrence of both conditions.
Results
This study has 80% power to detect an additive association
(P=0.05) with odds ratios of 1.15–1.23 for markers with minor
allele frequencies of 0.5–0.1 respectively. These values are based
on a disease prevalence of 0.4% in the general population and
linkage disequilibrium between markers of r2 = 0.8.
In phase 1 of the genotyping experiment MAFs for 53 markers
genotyped on cases were compared to MAF calculated from
historical controls from the 1958 BBC (genotyped and imputed
SNPs). Eight SNPs were excluded from further analysis; two
variants failed to meet imputation QC thresholds, four were
excluded based on their MAF and two failed the call rate criterion.
Of the remaining markers, 23 SNPs achieved a nominal P value of
0.1 (Table S1). This is significantly more markers than would be
expected by chance (P=4.8610210). Of these, one failed assay
design and 22 were taken forward for further genotyping in phase
2 of the experiment. A further marker failed QC thresholds in
phase 2 and was excluded from further analysis.
Considering the combined phase 1 and 2 data, experiment-wise
association (P,9.461024) was observed with seven genomic
regions (eight variants) and nominal association (P,0.05) was
detected for 18 markers (Table 1). Associations were tested in both
the overall cohort, and comparing cases with no clinical IBD
(n= 2613) with healthy controls. The frequency of AS cases with
coexistent IBD in our dataset is 5.8%. No significant difference
was noted in any of the findings having excluded cases with clinical
IBD, supporting these associations being relevant to the patho-
genesis of AS, rather than just coexistent IBD.
The strongest association was identified at genome-wide
significance for rs11584383 at chr1q32 (P=1.6610210) with
OR=0.74 (95% CI:0.68–0.82). This marker is downstream of and
flanked by KIF21B and the putative open reading frame C1orf106.
Convincing evidence of association was also identified for STAT3.
Association in STAT3 was detected at experiment-wise significance
for 2 markers (rs744166, P=2.661025, OR=0.84 (95% CI:0.77–
0.91); rs6503695, P=4.661024, OR=0.86 (95% CI:0.79–0.93)).
Another 2 variants within the gene showed more modest
association (rs2306580, P=0.023; rs4103200, P=1.961023) but
rs4103200 demonstrated nominal association in both phases of the
genotyping experiment.
Variants within or near CDKAL1 (rs6908425, P=1.161024,
OR=0.82 (95%CI:0.74–0.91)), IL12B (rs10045431, P=5.261025,
OR=0.83 (95% CI:0.76–0.91)), LRRK2/MUC19 (rs11175593,
P=9.961025, OR=1.92 (95% CI:1.38–2.67)) and at chr13q14
within C13orf31 (rs3764147, P=5.961024, OR=1.19 (95% CI:1-
08–1.31)) also demonstrated experiment-wise significant association
in this study. The function of CDKAL1 is poorly understood but the
gene has been associated with type-2-diabetes [12,13], and could
also possibly be a psoriasis risk locus [14].
Other nominal associations detected in this study include
3 variants within ATG16L1 and single SNPs at MST1, JAK2,
NKX2-3 and chr8q24. Further studies will be required to robustly
establish the significance of these findings. No association was
observed at TNFSF15 (rs4263839, P=0.3), consistent with
previous findings in AS [3,4], contrasting with findings in
undifferentiated spondyloarthritis [15], in which suggestive but
not genome-wide significant association has been reported
(rs4979459, P=4.961025). The peak IBD and spondyloarth-
ritis associations are with different SNPs that lie 85kb apart,
and thus if this gene is truly spondyloarthritis-associated, it is
likely that different genetic variants are associated with IBD and
spondyloarthritis.
This study also confirms the IL23R association with AS at
rs11465804 (P=1.261025), OR=0.65 (95% CI:0.54–0.79). In a
recent study, IL23R association with AS was confirmed with a
peak signal within the gene at rs11209026 (P=9.1610214) [4].
However, evidence of association at rs11465804 (3,432 bp away
from rs11209026) is much weaker, and was previously reported at
Author Summary
Ankylosing spondylitis is a common inflammatory arthritis
primarily affecting the spine and pelvis. The disease is
highly heritable (heritability.90%), and the major genetic
allele for the disease, HLA-B27, contributes approximately
half the genetic risk for the condition. Ankylosing spon-
dylitis and inflammatory bowel disease (Crohn’s disease
and ulcerative colitis) frequently occur together in the
same families and individuals, suggesting that they share
common risk factors. We tested whether genes associated
with Crohn’s disease are also associated with ankylosing
spondylitis and confirmed that the two diseases share
associations at chromosome 1q32 near KIF21B, STAT3,
IL12B, CDKAL1, LRRK2/MUC19, and chromosome 13q14.
These associations were present even in ankylosing
spondylitis cases with no clinical inflammatory bowel
disease. These findings greatly expand our understanding
of why these conditions co-occur and provide further
evidence of pleiotropy in human disease pathology. As the
genes IL23R, STAT3, and IL12B all influence Th17 lympho-
cyte differentiation/activation, this provides further evi-
dence implicating the Th17 lymphocyte subset in the
pathogenesis of ankylosing spondylitis.
Genetic Overlap between Crohn’s Disease and AS
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P=261024 in a study involving 1471 AS cases and 2125 matched
control individuals [3].
Discussion
The study presented here has identified new loci associated with
AS. The strongest of these associations was within an intergenic
region at chr1q32, near the gene KIF21B. The protein encoded by
this gene belongs to a family of kinesin motor proteins. Kinesins
are used for the transport of essential components along axonal
and dendritic microtubules by neurons. KIF5A has been associated
with rheumatoid arthritis, type-1-diabetes, and is close to a locus
recently reported to be associated with multiple sclerosis [16]. It is
possible that KIF5A is not the key associated gene at this
chromosome 12q13-14 locus. However, if confirmed as the true
disease-susceptibility gene for these autoimmune diseases, this
would strongly suggest alternate functions for the kinesin protein
family.
The STAT3 association is particularly significant because of its
role, along with IL23R, in the Th17 pathway. In response to
cytokine signaling through the IL-23R, STAT3 is activated by
phosphorylation and is translocated to the nucleus where it acts as a
transcriptional activator. Loss of function mutations of STAT3 result
in Job’s syndrome, in which an absence of Th17 lymphocytes leads
to recurrent severe infections, particularly with extracellular
bacteria [17].
The association with IL12B is of particular interest given the
associations of IL23R and STAT3 with AS. This gene has also been
shown to be associated with psoriasis in Caucasian and Chinese
populations [18,19]. IL12B encodes the p40 subunit common to
both IL-12 and IL-23 and again highlights the involvement of
Th17 cells in disease development. Another marker (rs1433048)
within the gene was also nominally associated (P,0.05) in the
combined analysis of the study. It is not clear at the LRRK2/
MUC19 locus which is the key associated gene with Crohn’s
disease, although a recent study suggests that LRRK2 is the more
likely to be truly disease-associated [20]. LRRK2, a member of the
leucine-rich repeat kinase family, is thought to be involved in the
process of autophagy. MUC19 encodes a mucin involved in
epithelial lining protection; altered intestinal permeability has long
been thought to be important in the pathogenesis of AS.
This study also provides further evidence of pleiotropic effects in
human disease pathology. A notable example of this is the
association of PTPN22 with several autoimmune conditions
including RA, T1D, CD and SLE. One of the 1st AS risk loci
identified, IL23R, is also associated with both forms of IBD
(ulcerative colitis and Crohn’s disease) as well as psoriasis. In this
study we provide further evidence for previously and newly
identified pleiotropic genes in autoimmune diseases. Given the
delicate nature of the immune system and the tight control of the
different cell populations it is not surprising that risk alleles of
important immune response genes may be associated across a
number of different conditions. These findings support the use of
study designs focusing on genes previously identified as being
associated with related conditions as being an efficient method for
identifying further genetic disease-associations.
This study of genes associated with Crohn’s disease has
identified definite genome-wide significant association with AS of
SNPs at chromosome 1q32 near KIF21B, and experiment-wise
association at five other novel-AS loci including STAT3, IL12B,
CDKAL1, LRRK2/MUC19, and at chr13q14. This confirms that
genes play an important part in the co-familiality of Crohn’s
disease and AS, and highlights the value of studies of potentially
pleiotropic genes in related diseases.
Materials and Methods
Cases included in the study were unrelated individuals with AS
of white European ancestry from the UK, USA, Canada and
Australia. The diagnosis of AS met the modified New York
definition criteria [21]. Ethnically matched unrelated control
individuals were selected from the 1958 British Birth Cohort
(BBC) and an Oxfordshire (UK) healthy blood donor cohort. All
patients gave informed, written consent, and the study was
approved by the relevant ethics review committees.
SNPs chosen for the study were selected from previously reported
risk loci identified in a CDGWA study [22]. Three candidate loci of
high interest were studied in greater depth (STAT3, IL12B
and ATG16L1). For these genes, tagging SNPs (r2$0.8) were
selected using Tagger in Haploview (http://www.broadinstitute.
org/haploview/haploview) and using the CEU population as a
reference panel from the International HapMap Project database
(http://www.hapmap.org/). Whenever assay design for selected
SNPs failed, perfect proxy SNPs (r2 = 1) were selected.
Genotyping was carried out in two phases. In phase 1, 53 SNPs
from 30 distinct genomic regions were selected for genotyping in
1,230 cases. Case genotype results were compared with historical
genotypes from 1,295 unrelated individuals from the 1958 British
Birth Cohort, which had been typed with both the Illumina
HumanHap 550 and Affymetrix SNP Array 5.0 microarrays.
Whenever selected markers were missing from the control
genotypes, imputation was carried out using MACH (http://
www.sph.umich.edu/csg/abecasis/MACH/index.html) against
the HapMap CEU dataset (reference panel). Imputed markers
with low overall quality scores (Q,0.95) and/or in low LD with
typed markers (r2,0.3) were excluded from further analysis. Only
genotypes with quality scores $0.95 were included in the study.
All nominally associated markers (P,0.1) were taken forward for
genotyping in phase 2 on 1,543 cases and 920 controls.
In phase 2, genotyping was performed using Sequenom
(Sequenom Inc., San Diego, USA), and Applied Biosystems
TaqMan and OpenArray technologies (Life Technologies, Carls-
bad, USA). For Sequenom, SNPs were assayed and typed using
iPLEX chemistry on a matrix assisted laser desorption/ionization
time-of-flight (MALDI_TOF) mass spectrometer. PCR reactions,
cycling conditions and post-PCR extension reactions were all
performed as recommended by the manufacturer. The iPLEX
reaction products were desalted and spotted on SpectroChip and
were processed and analysed in a compact mass spectrometer
(MassARRAY Workstation). MassARRAY Typer 4.0 software was
used for automated and manual genotype calling. OpenArray is a
new genotyping platform technology from Applied Biosystems for
medium-throughput experiment. SNPs were typed using TaqMan
genotyping chemistry supported on a metal-based array. DNA
samples were loaded and amplified on arrays as recommended by
the manufacturer. Arrays were scanned on the OpenArray NT
imager and genotypes were called using the OpenArray SNP
Genotyping analysis software. Whenever assay design or the
genotyping assay failed, markers were then genotyped using single
TaqMan probe technology as recommended by the manufacturer.
Association statistics were calculated using PLINK software
[23]. Analysis was carried out using the Cochran-Armitage test for
trend, excluding markers failing the following criteria; missingness
rate .0.1, minor allele frequency (MAF),0.01 and exact Hardy-
Weinberg equilibrium P,561025. We also excluded individuals
with a missing genotype rate .0.1 from the analysis. Experiment-
wise significance (P=9.461024) was determined by Bonferroni
correction based on the total number of markers genotyped in
phase1 of the study.
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Supporting Information
Table S1 Association study findings for phase 1 for all markers
genotyped. Markers with blank case and control MAF failed
genotyping. Positions based on NCBI reference sequence build
36.3. MAF, minor allele frequency; chr, chromosome.
Found at: doi:10.1371/journal.pgen.1001195.s001 (0.09 MB
DOC)
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